OBJECTIVES: The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition. BACKGROUND: The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear. METHODS:Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, aplacebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke. RESULTS: The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations. CONCLUSIONS: In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
RCT Entities:
OBJECTIVES: The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition. BACKGROUND: The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear. METHODS: Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke. RESULTS: The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations. CONCLUSIONS: In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
Authors: Kristen K Patton; Nona Sotoodehnia; Christopher DeFilippi; David S Siscovick; John S Gottdiener; Richard A Kronmal Journal: Heart Rhythm Date: 2010-10-30 Impact factor: 6.343
Authors: D Y Sahin; M Gür; Z Elbasan; N Y Koyunsever; C Türkoğlu; S Akyol; A Yıldırım; G Gözübüyük; B Ozaltun; M Caylı Journal: Herz Date: 2013-03-14 Impact factor: 1.443
Authors: C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg Journal: J Am Coll Cardiol Date: 2009-09-29 Impact factor: 24.094
Authors: Gerald Chi; James L Januzzi; Serge Korjian; Yazan Daaboul; Samuel Z Goldhaber; Adrian F Hernandez; Russell D Hull; Alex Gold; Alexander T Cohen; Robert A Harrington; C Michael Gibson Journal: J Thromb Thrombolysis Date: 2017-11 Impact factor: 2.300
Authors: Lori B Daniels; Gail A Laughlin; Paul Clopton; Alan S Maisel; Elizabeth Barrett-Connor Journal: J Am Coll Cardiol Date: 2008-08-05 Impact factor: 24.094
Authors: Torbjørn Omland; James A de Lemos; Marc S Sabatine; Costas A Christophi; Madeline Murguia Rice; Kathleen A Jablonski; Solve Tjora; Michael J Domanski; Bernard J Gersh; Jean L Rouleau; Marc A Pfeffer; Eugene Braunwald Journal: N Engl J Med Date: 2009-11-25 Impact factor: 91.245